Julia Rey
6 Papers
9 Citations
Julia Rey is an academic researcher. The author has contributed to research in topics: Breast cancer & Triple-negative breast cancer. The author has an hindex of 2, co-authored 6 publications.
Chat about Author
Papers
Predicting Prognosis of Breast Cancer Patients with Brain Metastases in the BMBC Registry-Comparison of Three Different GPA Prognostic Scores
Kerstin Riecke,Volkmar Müller,Rudolf Weide,Marcus Schmidt,Tjoung-Won Park-Simon,Volker Möbus,Christoph Mundhenke,Arkadius Polasik,Kristina Lübbe,T. Hesse,Elena Laakmann,Marc Thill,Peter A. Fasching,Carsten Denkert,Tanja Fehm,Valentina Nekljudova,Julia Rey,Sibylle Loibl,Isabell Witzel +18 more
TL;DR: In this article, three graded-prognostic-assessment (GPA) scores have been developed in order to estimate the prognosis of patients with brain metastases (BM) by objective criteria.
8
Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2).
Volker Möbus,Hans-Joachim Lück,Ekkehart Ladda,Peter Klare,Marcus Schmidt,Andreas Schneeweiss,Eva-Maria Grischke,Grischa Wachsmann,Helmut Forstbauer,Michael Untch,Frederik Marmé,Jens-Uwe Blohmer,Christian Jackisch,Jens Huober,Elmar Stickeler,Mattea Reinisch,Theresa Link,Bruno Valentin Sinn,Wolfgang Janni,Carsten Denkert,Jenny Furlanetto,Knut Engels,Christine Solbach,Sabine Schmatloch,Julia Rey,Nicole Burchardi,Sibylle Loibl,Gbg,Ago-B +28 more
TL;DR: The GAIN-2 trial as mentioned in this paper was designed to identify a superior intense dose-dense (idd) strategy for high-risk patients with early breast cancer, at which the predefined futility boundary was crossed.
8
GAIN-2: Neo-/adjuvant phase III trial to compare intense dose-dense chemotherapy (CT) to tailored dose-dense CT in patients (pts) with high risk early breast cancer (EBC): Results on safety and interim invasive disease-free survival (iDFS).
Volker Moebus,Hans-Joachim Lueck,Ekkehart Ladda,Peter Klare,Marcus Schmidt,Andreas Schneeweiss,Michael Untch,Frederik Marmé,Jens Huober,Elmar Stickeler,Mattea Reinisch,Theresa Link,Bruno Valentin Sinn,Jenny Furlanetto,Toralf Reimer,Christine Solbach,Sabine Schmatloch,Julia Rey,Nicole Burchardi,Sibylle Loibl +19 more
TL;DR: GAIN-2 compared efficacy and safety of intense, dose-dense epirubicin, nab-paclitaxel, and cyclophosphamide against dose- dense, doses-tailored epirUBicin/ cyclophos...
3
Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC).
Sibylle Loibl,Andreas Schneeweiss,Jens Huober,Michael Braun,Julia Rey,Jens Uwe Blohmer,Jenny Furlanetto,Dirk Michael Zahm,Claus Hanusch,Jörg Thomalla,Christian Jackisch,Peter Staib,Theresa Link,Kerstin Rhiem,Christine Solbach,Peter A. Fasching,Nicole Burchardi,Carsten Denkert,Michael Untch +18 more
TL;DR: The GeparNuevo trial investigated the addition of durvalumab, an anti-PD-L1 checkpoint inhibitor (CPI), to standard neoadjuvant chemotherapy (NACT) in patients with early TNBC.
Characteristics and Clinical Outcome of Breast Cancer Patients with Asymptomatic Brain Metastases.
Elena Laakmann,Isabell Witzel,T Neunhöffer,Rudolf Weide,Marcus Schmidt,Tjoung Won Park-Simon,Volker Möbus,Christoph Mundhenke,Arkadius Polasik,Kristina Lübbe,T. Hesse,K Riecke,Marc Thill,Peter A. Fasching,Carsten Denkert,Tanja Fehm,Valentina Nekljudova,Julia Rey,Sibylle Loibl,Volkmar Müller +19 more
TL;DR: It is suggested that women could be better off if their brain metastases are diagnosed before they begin to cause symptoms, and despite less intensive local BM therapy still have a better outcome than patients who present with symptomatic BM.